Physician profile
James W Levine
NPI 1093793838
$129,925.54
in general payments reported to CMS, 2019-2025
15 companies · $26K in 2025
The $26K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $12K · 2021: $6,329 · 2022: $7,499 · 2023: $8,280 · 2024: $21K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $7,808 · Consulting Fee: $5,613 · Food and Beverage: $3,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,810.00 |
| Travel and Lodging | $7,807.76 |
| Consulting Fee | $5,612.50 |
| Food and Beverage | $3,341.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $55,552.57 | 2020-2025 | |
| Lilly USA, LLC | $51,569.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $6,411.69 | 2019-2025 | |
| Gilead Sciences, INC. | $5,698.21 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $4,499.89 | 2019 | |
| Horizon Therapeutics Plc | $2,820.81 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $1,244.21 | 2020-2025 | Saphnelo |
| Ucb, INC. | $520.71 | 2024-2025 | Bimzelx |
| Abbvie INC. | $467.71 | 2020-2025 | |
| Amgen INC. | $348.54 | 2019-2024 | Tavneos, Enbrel, Otezla |
| Janssen Biotech, INC. | $322.75 | 2019-2024 | Tremfya |
| Glaxosmithkline, LLC. | $160.24 | 2019-2024 | Benlysta |
| Janssen Scientific Affairs, LLC | $130.14 | 2023 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.30 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $83.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.